Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OFSET
NCT05879926Phase 3Recruiting
- Sponsor
- NRG Oncology
- Start
- Oct 2023
- Primary completion
- Jan 2032
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, open-label trial in breast cancer (2 arms), sponsored by NRG Oncology. Primary endpoint: Invasive breast cancer-free survival at 11 years. Started Oct 2023; status: recruiting.
02
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05879926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05879926.